Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $8.29.
VTYX has been the subject of a number of research reports. Canaccord Genuity Group decreased their price objective on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, August 12th. Oppenheimer decreased their price objective on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, June 6th. HC Wainwright restated a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research note on Monday, September 23rd. Finally, Wells Fargo & Company decreased their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th.
Get Our Latest Stock Analysis on Ventyx Biosciences
Institutional Inflows and Outflows
Ventyx Biosciences Stock Performance
NASDAQ:VTYX opened at $2.11 on Thursday. The company has a market cap of $149.11 million, a PE ratio of -0.65 and a beta of 0.37. Ventyx Biosciences has a 52-week low of $1.79 and a 52-week high of $31.01. The stock has a 50-day simple moving average of $2.21 and a 200 day simple moving average of $3.44.
Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. On average, research analysts predict that Ventyx Biosciences will post -2.14 earnings per share for the current fiscal year.
Ventyx Biosciences Company Profile
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Featured Stories
- Five stocks we like better than Ventyx Biosciences
- 5 Top Rated Dividend Stocks to Consider
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Quiet Period Expirations Explained
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Why is the Ex-Dividend Date Significant to Investors?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.